Clinical Use Of Calcium Channel Antagonist Drugs

Calcium antagonists are now regarded as the most important advance in cardiac drug therapy since the advent of beta-adrenergic blocking agents. Acting ba sically as vasodilators-though with many other com plex mechanisms especially in the case of the anti arrhythmic calcium antagonists, these agents have grown in importance to become among the therapeutic agents of first choice for angina pectoris and hyper tension. The major aim of the present book is to present the clinician with the information needed for the practical use of calcium antagonists. What do all the numerous and often conflicting trials say? Do these agents really work? If so, which agent and in what dose? How do the three front runners, verapamil, nifedipine and diltia zem compare in the efficacy and side-effects with each other? How do the new second generation agents, now entering the North American market, slot in and com pare with the three first-liners? When the gloss is taken away from the advertisements, what is really left? The strong clinical bias of the present book should be complimented by further reading of books slanted towards fundamentals. One of the most important and recent of these is that by Dr Winifred Nayler (Calcium Antagonists, Academic Press, 1988). That book should be basic for essential background knowledge in the area of calcium antagonists. The important basic contribu tions of Fleckenstein deserve emphasis.

The main effect of calcium channel blockers is the blockade of calcium entry into cells through voltage operated calcium channels. This volume gives a comprehensive overview of the different classes of CCBs and their various effects. It covers historical development, pharmacology, clinical aspects, and perspectives. All chapters are written by Prof. T. Godfraind, a world leading expert in the field.

This thoroughly revised and expanded new edition presents the current state of knowledge of the diverse applications of calcium antagonists and makes recommendations about their appropriate use. New sections have been added on Clinical Pharmacology and Metabolic Effects. Sixteen new chapters have been added on such topics as Pharmacogenetics of Hypertension: Using Gene Markers to Infer Pathogenesis and Guide Therapy, New Pharmacologic Directions for Calcium Channel Blockers, Calcium Channel Blocker Use in End-Stage Renal Disease: Pharmacokinetics and Pharmacodynamics, and many others. Significantly expanded from previous edition with 16 new chapters on hot topics A comprehensive reexamination of the safety of calcium antagonists in light of many newly reported clinical trials Elucidates the evolving role of calcium antagonists in the antihypertensive armamentarium, especially in the patient with diabetes Explores beneficial effects of calcium antagonists in attenuating atherosclerosis in the context of newly reported clinical trials, including ELSA. Written by world-renowned experts in the field Emphasizes evidence-based studies New chapters have been added on such topics as Pharmacogenetics of Hypertension: Using Gene Markers to Infer Pathogenesis and Guide Therapy, New Pharmacologic Directions for Calcium Channel Blockers, Calcium Channel Blocker Use in End-Stage Renal Disease: Pharmacokinetics and Pharmacodynamics.

Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury.

Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, Sixteenth Edition, Seven Volume Set builds on the success of the 15 previous editions, providing an extensively reorganized and expanded resource that now comprises more than 1,500 individual drug articles with the most complete coverage of adverse reactions and interactions found anywhere. Each article contains detailed and authoritative information about the adverse effects of each drug, with comprehensive references to the primary literature, making this a must–have reference work for any academic or medical library, pharmacologist, regulatory organization, hospital dispensary, or pharmaceutical company. The online version of the book provides an unparalleled depth of coverage and functionality by offering convenient desktop access and enhanced features such as increased searchability, extensive internal cross-linking, and fully downloadable and printable full-text, HTML or PDF articles. Enhanced encyclopedic format with drug monographs now organized alphabetically Completely expanded coverage of each drug, with more than 1,500 drug articles and information on adverse reactions and interactions Clearer, systematic organization of information for easier reading, including case histories to provide perspective on each listing Extensive bibliography with over 40,000 references A must–have reference work for any academic or medical library, pharmacologist, regulatory organization, hospital dispensary, or pharmaceutical company

Featuring more than 4100 references, Drug-Induced Liver Disease will be an invaluable reference for gastroenterologists, hepatologists, family physicians, internists, pathologists, pharmacists, pharmacologists, and clinical toxicologists, and graduate and medical school students in these disciplines.

In the past two decades a number of studies have shown that abnormalities in the function and structure of coronary microcirculation can be detected in several cardiovascular diseases. On the basis of the clinical setting in which it occurs, coronary microvascular dysfunction (CMD) can be classified into four types: CMD in the absence of any other cardiac disease; CMD in myocardial diseases; CMD in obstructive epicardial coronary artery disease; and iatrogenic CMD. In some instances CMD represents an epiphenomenon, whereas in others it represents an important marker of risk or may contribute to the pathogenesis of myocardial ischemia, thus becoming a possible therapeutic target. This book provides an update on coronary physiology and a systematic assessment of microvascular abnormalities in cardiovascular diseases, in the hope that it will assist clinicians in prevention, detection and management of CMD in their everyday activity.